Erythropoietin (EPO) Drugs Market Trends, Business Overview, Industry Growth and Forecast to 2028
The Erythropoietin (EPO) Drugs Market size is expected to grow at an annual average of 4% during 2022-2028. Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that induces red blood cell production in the bone marrow through red blood cell production. Erythropoietin drugs were developed to treat end-stage renal disease (ESRD) disease and anemia conditions resulting from dialysis procedures. Following the ESRD anemia condition, the EPO drug was approved for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approval and the high success rate of EPO application for chemotherapy-induced anemia, the original biopharmaceutical company turned its attention to another form of induced anemia, namely ART-induced anemia (among HIV patients). turned
The following segmentation are covered in this report:
By Application
- Hematology
- Kidney Disorder
- Cancer
- Others
By Product Type
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Company Profile
- Johnson & Johnson
- Amgen Inc.
- Roche, Hospira Inc.
- Biocon
- LG Life Sciences Ltd.
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals
- Ranbaxy Laboratories Ltd
- Celltrion, Inc.
Scope of the report
The research study analyses the Erythropoietin (EPO) Drugs Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:
Recent developments
- Market overview and growth analysis
- Import and export overview
- Volume analysis
- Current market trends and future outlook
- Market opportunistic and attractive investment segment
Geographic coverage
- North america market size and/or volume
- Latin america market size and/or volume
- Europe market size and/or volume
- Asia-pacific market size and/or volume
- Rest of the world market size and/or volume
Key Questions Answered by Erythropoietin (EPO) Drugs Market Report
- What was the Erythropoietin (EPO) Drugs Market size in 2021 and 2022; what are the estimated growth trends and market forecast (2022-2028)
- What will be the CAGR of Market during the forecast period (2022-2028)?
- Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2022-2028).
- Which manufacturer/vendor/players in the Erythropoietin (EPO) Drugs Market was the market leader in 2021?
- Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.
The report will be delivered within 48-72 hours after payment confirmation